You are here

Replimune

Catalysts ahead for the smaller players

EP Vantage

Wed, 12/21/22 - 11:19 am

BioXcel Therapeutics

Calliditas Therapeutics

Esperion Therapeutics

Nektar Therapeutics

Oramed Pharmaceuticals

Pliant Therapeutics

Selecta Biosciences

Swedish Orphan Biovitrum

Vera Therapeutics

Viking Therapeutics

Replimune’s melanoma success looks more than skin deep

EP Vantage

Fri, 12/9/22 - 10:34 am

clinical trials

Oncolytic virus experts at Replimune reload with $200M loan as biotech collects clinical data

Endpoints

Fri, 10/7/22 - 10:46 am

oncolytic viruses

Fourth-quarter data for the little guys

EP Vantage

Mon, 10/3/22 - 10:01 am

Replimune axes CMO role and CMO Pirzkall along with it

Fierce Biotech

Thu, 08/26/21 - 10:55 am

Replimune heads for the liver

EP Vantage

Fri, 06/4/21 - 10:39 am

oncolytic viruses

A unicorn joins this week’s stampede of biotechs into the red-hot Nasdaq casino

Endpoints

Mon, 07/16/18 - 09:11 am

Constellation Pharma

Crinetics Pharmaceuticals

Rubius Therapeutics

Next-gen oncolytics upstart Replimune grabs a $30M transatlantic venture round

Fierce Biotech

Thu, 09/24/15 - 11:44 am